share_log

Vivos Therapeutics | 424B1: Prospectus

Vivos Therapeutics | 424B1: Prospectus

Vivos Therapeutics | 424B1：募資說明書
美股sec公告 ·  08/08 17:24
Moomoo AI 已提取核心訊息
Vivos Therapeutics, a medical technology company specializing in the treatment of dentofacial abnormalities and sleep apnea, has filed a prospectus with the SEC detailing the resale of shares by a selling stockholder. The selling stockholder, V-CO Investors LLC, affiliated with private equity firm New Seneca Partners, Inc., is offering 169,498 shares of common stock, 3,050,768 shares issuable upon exercise of a Pre-Funded Warrant, and 3,220,266 shares issuable upon exercise of a Common Stock Purchase Warrant. These securities were acquired as part of a private placement that closed on June 10, 2024. Vivos Therapeutics will not receive any proceeds from the sale of the shares, but may receive funds if the warrants are exercised for cash. The shares are listed on The Nasdaq Capital Market under the symbol 'VVOS'. The selling stockholder may sell the shares through various methods including brokerage transactions, block trades, or directly to purchasers. The timing and amount of any sale are at the discretion of the selling stockholder.
Vivos Therapeutics, a medical technology company specializing in the treatment of dentofacial abnormalities and sleep apnea, has filed a prospectus with the SEC detailing the resale of shares by a selling stockholder. The selling stockholder, V-CO Investors LLC, affiliated with private equity firm New Seneca Partners, Inc., is offering 169,498 shares of common stock, 3,050,768 shares issuable upon exercise of a Pre-Funded Warrant, and 3,220,266 shares issuable upon exercise of a Common Stock Purchase Warrant. These securities were acquired as part of a private placement that closed on June 10, 2024. Vivos Therapeutics will not receive any proceeds from the sale of the shares, but may receive funds if the warrants are exercised for cash. The shares are listed on The Nasdaq Capital Market under the symbol 'VVOS'. The selling stockholder may sell the shares through various methods including brokerage transactions, block trades, or directly to purchasers. The timing and amount of any sale are at the discretion of the selling stockholder.
醫療技術公司Vivos Therapeutics專注於治療牙面畸形和睡眠呼吸暫停，並向SEC提交了擬轉售股東出售股票的招股書。與私募股權公司New Seneca Partners, Inc.相關聯的售出股東V-CO Investors LLC，提供了169,498股普通股，3,050,768股可在行使預先擬入行權證時發行以及3,220,266股可在行使普通股購股權時發行。這些證券是作爲於2024年6月10日結束的定向增發的一部分而獲得的。Vivos Therapeutics將不會從股票銷售中獲得任何收益，但如果權證以現金行使，則可能會獲得資金。這些股票在納斯達克資本市場上以「VVOS」爲標的進行交易。售出股東可以通過多種方式出售股票，包括經紀交易、大宗交易或直接銷售給購買者。任何銷售的時間和數量均由售出股東決定。
醫療技術公司Vivos Therapeutics專注於治療牙面畸形和睡眠呼吸暫停，並向SEC提交了擬轉售股東出售股票的招股書。與私募股權公司New Seneca Partners, Inc.相關聯的售出股東V-CO Investors LLC，提供了169,498股普通股，3,050,768股可在行使預先擬入行權證時發行以及3,220,266股可在行使普通股購股權時發行。這些證券是作爲於2024年6月10日結束的定向增發的一部分而獲得的。Vivos Therapeutics將不會從股票銷售中獲得任何收益，但如果權證以現金行使，則可能會獲得資金。這些股票在納斯達克資本市場上以「VVOS」爲標的進行交易。售出股東可以通過多種方式出售股票，包括經紀交易、大宗交易或直接銷售給購買者。任何銷售的時間和數量均由售出股東決定。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息